Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial
2018 ◽
Vol 84
(6)
◽
pp. 1136-1145
◽
Arnab Mukherjee
◽
Anasuya Hazra
◽
Mike K. Smith
◽
Steven W. Martin
◽
Diane R. Mould
◽
...
2011 ◽
Vol 378
(9792)
◽
pp. 676-683
◽
John GF Cleland
◽
John R Teerlink
◽
Roxy Senior
◽
Evgeny M Nifontov
◽
John JV Mc Murray
◽
...
2014 ◽
Vol 146
(5)
◽
pp. S-367-S-368
◽
Arnab Mukherjee
◽
Kaori Ito
◽
Mike K. Smith
◽
Chinyu Su
◽
Wojciech Niezychowski
2018 ◽
Vol 12
(10)
◽
pp. 1158-1169
◽
Bruce E Sands
◽
William J Sandborn
◽
Brian G Feagan
◽
Gary R Lichtenstein
◽
Hongyan Zhang
◽
...
William J. Sandborn
◽
Marc Ferrante
◽
Bal R. Bhandari
◽
Elina Berliba
◽
Toshifumi Hibi
◽
...
2019 ◽
Vol 13
(Supplement_1)
◽
pp. S054-S054
W J Sandborn
◽
M Ferrante
◽
B R Bhandari
◽
E Berliba
◽
T Hibi
◽
...
2016 ◽
Vol 150
(4)
◽
pp. S590
◽
Omoniyi J. Adedokun
◽
Daphne Chan
◽
Lakshmi Padgett
◽
Yan Xu
◽
Jeffrey S. Hyams
◽
...
2016 ◽
Vol 11
(1)
◽
pp. 1-2
◽
2020 ◽
Vol 158
(6)
◽
pp. S-284-S-285
Boyd Steere
◽
Klaus Gottlieb
◽
Jochen Schmitz
◽
Richard Higgs
◽
Bochao Jia
◽
...
2021 ◽
Vol 160
(3)
◽
pp. S8-S9
William Sandborn
◽
Brian Feagan
◽
Douglas Wolf
◽
Geert D’Haens
◽
Séverine Vermeire
◽
...
2021 ◽
Vol 161
(2)
◽
pp. e29-e30
Baili Chen
◽
Jie Zhong
◽
Qian Cao
◽
Xiuling Li
◽
Feng Pan
◽
...